Levacetylmethadol - Misplaced Pages

(Redirected from Orlaam) Synthetic opioid drug "LAAM" redirects here. For other uses, see Laam (disambiguation). Pharmaceutical compound

Levacetylmethadol
Clinical data


Trade names	OrLAAM
Routes of administration	By mouth
ATC code	N07BC03 (WHO)
Legal status
Legal status	AU: S8 (Controlled drug) CA: Schedule I DE: Anlage III (Special prescription form required) US: Schedule II
Pharmacokinetic data
Protein binding	~80%
Metabolism	CYP3A4
Elimination half-life	2.6 days
Identifiers
IUPAC name (3S,6S)-(6-dimethylamino-4,4-diphenyl-heptan-3-yl) acetate
CAS Number	1477-40-3 43033-72-3 (hydrochloride)
PubChem CID	15130
IUPHAR/BPS	7212
DrugBank	DB01227
ChemSpider	14401
UNII	R3B637Y991
KEGG	D04716
ChEMBL	ChEMBL1514
CompTox Dashboard (EPA)	DTXSID3023211
Chemical and physical data
Formula	C₂₃H₃₁NO₂
Molar mass	353.506 g·mol
3D model (JSmol)	Interactive image
SMILES CC(C(C(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2)OC(=O)C
InChI InChI=1S/C23H31NO2/c1-6-22(26-19(3)25)23(17-18(2)24(4)5,20-13-9-7-10-14-20)21-15-11-8-12-16-21/h7-16,18,22H,6,17H2,1-5H3/t18-,22-/m0/s1 Key:XBMIVRRWGCYBTQ-AVRDEDQJSA-N
(what is this?) (verify)

Levacetylmethadol (INN), levomethadyl acetate (USAN), OrLAAM (trade name) or levo-α-acetylmethadol (LAAM) is a synthetic opioid similar in structure to methadone. It has a long duration of action due to its active metabolites.

Medical uses

LAAM is indicated as a second-line treatment for the treatment and management of opioid dependence if patients fail to respond to drugs like methadone or buprenorphine.

LAAM is used as an oral solution of LAAM hydrochloride at a concentration of 10 mg/mL in bottles of 120 and 500 mL under the brand name Orlaam. The first dose of LAAM for patients who have not started treatment with methadone is 20–40 mg. The first dose for patients who have been receiving methadone will be a little higher than the amount of methadone that was being taken every day, but not more than 120 mg. Afterwards, the dosage may be adjusted as needed. Unlike methadone, which requires daily administration, LAAM is administered two to three times a week.

Pharmacology

Pharmacodynamics

LAAM acts as a μ-opioid receptor agonist.
It also acts as a potent, noncompetitive α₃β₄ neuronal nicotinic acetylcholine receptor antagonist.

Pharmacokinetics

LAAM undergoes extensive first-pass metabolism to the active demethylated metabolite nor-LAAM, which is further demethylated to a second active metabolite, dinor-LAAM. These metabolites are more potent than the parent drug.

Chemistry

LAAM, or levomethadyl acetate, is the levo isomer of acetylmethadol, or α-methadyl acetate. The dextro isomer, d-alphacetylmethadol (d-α-acetylmethadol), is more potent but shorter acting. The levo isomer is also less toxic with an LD₅₀ in mice of 110 mg/kg s.c. and 172.8 mg/kg orally as opposed to LD₅₀s of 61 mg/kg s.c. and 118.3 mg/kg orally for dl-α-methadyl acetate. It has a melting point of 215 °C and a molecular weight of 353.50. β-methadyl acetate also exists, however it is more toxic and less active than α-methadyl acetate and has no current medical use.

History

LAAM was approved in 1993 by the U.S. Food and Drug Administration for use in the treatment of opioid dependence. In 2001, LAAM was removed from the European market due to reports of life-threatening ventricular rhythm disorders. In 2003, Roxane Laboratories, Inc. discontinued Orlaam in the US.

Society and culture

Legal status

Before August 1993, LAAM was classified as a schedule I drug in the United States. LAAM is not approved for use in Australia and Canada. At present, it is a Schedule II Narcotic controlled substance in the United States with a DEA ACSCN of 9648 and a national aggregate annual manufacturing quota of 4 grams as of 2013.

References

US 3021360, Pholand A, "3-Acetoxy-4,4-diphenyl-6-methylaminoheptane", issued 12 February 1962, assigned to Eli Lilly and Company
US 2565592, Clark RL, "Alpha-d1-4-acetoxy-1-methyl-3,3-diphenylhexylamine and salts", issued 28 August 1951, assigned to Merck & Company
Xiao Y, Smith RD, Caruso FS, Kellar KJ (October 2001). "Blockade of rat α3β4 nicotinic receptor function by methadone, its metabolites, and structural analogs". The Journal of Pharmacology and Experimental Therapeutics. 299 (1): 366–71. PMID 11561100.
"EMEA Public Statement on the Recommendation to Suspend the Marketing Authorisation for Orlaam (Levacetylmethadol) in the European Union" (PDF). The European Agency for the Evaluation of Medicinal Products. 19 April 2001. Archived from the original (PDF) on 4 February 2017. Retrieved 4 April 2016.
"Orlaam (levomethadyl acetate hydrochloride)". US FDA Safety Alerts. 20 August 2013. Archived from the original on 10 October 2013.

External links

"LAAM Drug Information". Drugs.com.
"Monograph for Orlaam". RxList. Archived from the original on 2008-07-19.
"Levomethadyl Acetate". DrugBank.

v t e Treatment of drug dependence (N07B)
Nicotine dependence	Bupropion Cytisine Lobeline Mecamylamine Varenicline AATooltip Adrenergic agonist (Clonidine)
Alcohol dependence	AD inhibitor Disulfiram Acamprosate Calcium carbimide Hydrogen cyanamide General anesthetics Nitrous oxide Opioid antagonists Naltrexone Nalmefene Topiramate AATooltip Adrenergic agonist (Clonidine) Baclofen Phenibut
Opioid dependence	AATooltip Adrenergic agonist (Clonidine Lofexidine) Ibogaine Opioids Buprenorphine (+naloxone) Levacetylmethadol Methadone Dihydrocodeine Dihydroetorphine Hydromorphone (extended-release) Morphine (extended-release) Opioid antagonists (Naltrexone Nalmefene)
Benzodiazepine dependence	AATooltip Adrenergic agonist (Clonidine) Benzodiazepines (Diazepam Lorazepam Chlordiazepoxide Oxazepam) Barbiturates (Phenobarbital)